Pembrolizumab for progressive multifocal leukoencephalopathy due to primary immunodeficiency

Clemens Küpper, MD, Johanna Heinrich, MD, Katharina Kamm, MD, Veit Bücklein, MD, Simon Rothenfusser, MD, and Andreas Straube, MD

Neurol Neuroimmunol Neuroinflamm 2019;6:e628. doi:10.1212/NXI.0000000000000628

Progressive multifocal leukoencephalopathy (PML) is a devastating demyelinating disease of the CNS, which develops almost exclusively in immunocompromised patients and is caused by JC virus (JCV), a common polyomavirus. So far, treatment efficacy is only modest if the compromised immune system cannot be restored. A potential treatment target is the programmed cell death protein 1 (PD-1) whose expression on CD4+ and CD8+ T lymphocytes has been shown to be elevated in patients with PML. Moreover, blocking of the PD-1 receptor resulted in increased JCV-specific T-cell immune response in a subgroup of patients with PML. Recently, pembrolizumab, a humanized monoclonal antibody directed against PD-1, was reported for the first time to be a promising option for PML with treatment responses in 6 of 9 patients. Here, we describe another patient with PML who did not benefit from treatment with pembrolizumab.

Case report

The patient is a 42-year-old man with a primary immunodeficiency (PID) syndrome diagnosed previously as common variable immunodeficiency with low natural killer cells. No mutation in a known PID gene was found by whole-exome sequencing, and he had been under immunoglobulin replacement therapy for several years. Since 2016, his previously normal CD4+ T-cell numbers started to decline, and he progressed to a late-onset combined immunodeficiency reaching 180–150 CD4+ T cells/μL in May 2018 when he developed anopia of the lower right quadrant. In August 2018, a cranial MRI showed a fluid-attenuated inversion recovery hypointense cortical lesion of the left occipital lobe suggestive of PML. A CSF PCR detected JCV (38 copies/mL), and PML was diagnosed. In October 2018, the patient gave written informed consent to receive off-label treatment with pembrolizumab. The intervention was performed in accordance with the regulations of the Ethics Committee of the Ludwig Maximilians University of Munich. Pembrolizumab was started with 2 mg/kg biweekly. The analysis of PD-1 expression on CD4+ and CD8+ T lymphocytes in CSF and peripheral blood before and after the first course of pembrolizumab by flow cytometry showed reduced detection of PD-1 indicative of effective PD-1 blockade by pembrolizumab (figure, A). However, in the following weeks, the patient developed cortical blindness, memory disturbance, hallucinations, and aggressive behavior, whereas the CSF JC viral load and the PML lesions on MRI increased until administration of the fifth course of pembrolizumab (figure, B). There was no contrast enhancement detected on the cerebral MRIs. In February 2019, the patient developed left-sided hemiparesis and coma. Although a final evaluation had shown a decreasing trend for JC viral load in the CSF, pembrolizumab was stopped as in view of the dramatic clinical deterioration, further treatment did not seem appropriate anymore. The patient finally died under supportive care 2 weeks later.
In summary, in our case, PML treatment with pembrolizumab failed to change the disease outcome. Because responses to pembrolizumab can happen after the fifth biweekly course, we do not know whether pembrolizumab is not effective in patients with PID syndromes leading to low CD4+ T cells or whether we have just started our treatment too late to stop the disease in time (previous fatal brain damage). The optimal treatment strategy for these conditions has to be further determined in larger studies.

This case report gives Class IV evidence that pembrolizumab treatment in patients with PML due to PID leading to low CD4+ T cells might not be effective in general or when given late in the disease course.

Study funding
No targeted funding reported.

Disclosure
The authors report no disclosures. Disclosures available: Neurology.org/NN.

Publication history
Received by Neurology: Neuroimmunology & Neuroinflammation July 3, 2019. Accepted in final form August 5, 2019.

Appendix Authors

<table>
<thead>
<tr>
<th>Author</th>
<th>Location</th>
<th>Role</th>
<th>Contribution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clemens Küpper</td>
<td>Ludwig Maximilians University, Munich, Germany</td>
<td>Author</td>
<td>Designed and conceptualized the study; analyzed the data; and drafted the manuscript for intellectual content</td>
</tr>
</tbody>
</table>
References

Pembrolizumab for progressive multifocal leukoencephalopathy due to primary immunodeficiency
Clemens Küpper, Johanna Heinrich, Katharina Kamm, et al.
Neurol Neuroimmunol Neuroinflamm 2019;6:e628
DOI 10.1212/NXI.0000000000000628

This information is current as of October 9, 2019

Updated Information & Services
including high resolution figures, can be found at:
http://nn.neurology.org/content/6/6/e628.full.html

References
This article cites 7 articles, 0 of which you can access for free at:
http://nn.neurology.org/content/6/6/e628.full.html##ref-list-1

Citations
This article has been cited by 5 HighWire-hosted articles:
http://nn.neurology.org/content/6/6/e628.full.html##otherarticles

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
http://nn.neurology.org/misc/about.xhtml#permissions

Reprints
Information about ordering reprints can be found online:
http://nn.neurology.org/misc/addir.xhtml#reprintsus